| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60505-4532-02 | 60505-4532 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 9, 2023 | In Use | |
| 00085-1235-01 | 00085-1235 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Oct 3, 2010 | No Longer Used | ||
| 59572-0215-93 | 59572-0215 | Thalidomide | Thalomid | 150.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 20, 2007 | In Use | |
| 00115-1476-59 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 28, 2011 | Jun 1, 2017 | No Longer Used |
| 57894-0503-01 | 57894-0503 | Daratumumab and hyaluronidase-fihj (human recombinant) | Darzalex Faspro | 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL | Immunotherapy | Monoclonal Antibody | CD38 | Subcutaneous | May 1, 2020 | In Use | |
| 00310-4500-12 | 00310-4500 | Durvalumab | Imfinzi | 120.0 mg/2.4mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 1, 2017 | In Use | |
| 78206-0147-01 | 78206-0147 | trastuzumab | Ontruzant | 150.0 mg/1 | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 1, 2021 | In Use | |
| 81481-0803-01 | 81481-0803 | Nogapendekin alfa inbakicept-pmln | ANKTIVA | 400.0 ug/.4mL | Immunotherapy | Cytokine | IL-15 (⍺,β,ɣ) | Intravesical | May 6, 2024 | In Use | |
| 00007-3261-01 | 00007-3261 | Tositumomab, Iodine I-131 | Bexxar Dosimetric | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Feb 13, 2014 | No Longer Used | ||
| 60505-4533-02 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 70114-0340-01 | 70114-0340 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
| 67457-0847-44 | 67457-0847 | Trastuzumab | OGIVRI | 420.0 mg/ 20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov 29, 2019 | Apr 30, 2027 | In Use |
| 00006-3026-04 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug 1, 2019 | In Use | |
| 55513-0160-01 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Dec 18, 2014 | In Use | ||
| 73536-0500-01 | 73536-0500 | ROPEGINTERFERON ALFA-2B | BESREMi | 500.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 12, 2021 | In Use | |
| 59572-0210-15 | 59572-0210 | Thalidomide | Thalomid | 100.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 20, 2003 | In Use | |
| 63304-0042-27 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 00002-7716-01 | 00002-7716 | Necitumumab | Portrazza | 16.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Nov 24, 2015 | In Use | |
| 50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
| 59572-0402-00 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use | |
| 00085-1287-02 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
| 57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
| 42238-0111-01 | 42238-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | Jan 17, 2018 | No Longer Used |
| 55513-0164-01 | 55513-0164 | Traztuzumab-anns, trastuzumab-anns | Kanjinti | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 1, 2023 | Jun 30, 2025 | No Longer Used | |
| 76282-0697-48 | 76282-0697 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use |
Found 11888 results — Export these results
Home